-+ 0.00%
-+ 0.00%
-+ 0.00%

Eledon presents new long-term Phase 2 BESTOW kidney transplant data for tegoprubart at ATC

PUBT·05/20/2026 20:06:39
Listen to the news
Eledon presents new long-term Phase 2 BESTOW kidney transplant data for tegoprubart at ATC
  • Eledon Pharmaceuticals scheduled new long-term data from its Phase 2 BESTOW kidney transplant program for presentation at the American Transplant Congress in Boston on June 20-24, 2026.
  • The update will cover longer follow-up from tegoprubart studies aimed at preventing kidney transplant rejection, with a focus on safety and efficacy outcomes.
  • An oral presentation is set for June 22, 2026, with an accompanying conference call the same morning to discuss the updated BESTOW results and extension-study findings.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eledon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605201605PRIMZONEFULLFEED9724176) on May 20, 2026, and is solely responsible for the information contained therein.